Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Molecular & Cellular Oncology|June 17, 2016
Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinomaMatthew Hellmann, Naiyer Rizvi, Jedd D Wolchok, et al.
The Journal of Arthroplasty|August 15, 2009
The estimated magnitude and direct hospital costs of prosthetic joint infections in the United States, 1997 to 2004Matthew Hellmann, Supriya D Mehta, David M Bishai, et al.
Oncoimmunology|October 10, 2015
Genetics and immunology: reinvigoratedAlexandra Snyder, Vladimir Makarov, Matthew Hellmann, et al.
Cancer|June 22, 2010
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphomaJeremy S Abramson, Matthew Hellmann, Jeffrey A Barnes, et al.
Biorxiv : the Preprint Server for Biology|July 18, 2023
Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumorsGabriel Espinosa-Carrasco, Aurora Scrivo, Paul Zumbo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN TrialJamie E Chaft, Mark Dunphy, Jarushka Naidoo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2023
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung CancerMiguel Lopez de Rodas, Yvonne Wang, Gang Peng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2018
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 StudyScott Gettinger, Leora Horn, David Jackman, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance statusJoao V Alessi, Biagio Ricciuti, Elizabeth Jiménez-Aguilar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2017
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i>-Mutant Non-Small Cell Lung CancerKathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, et al.
Pageof 2